ArticleDermatology and therapy2025

Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study.

Tiago Torres et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.